https://pbs.twimg.com/media/FhdlIedXgAcgzGf.jpg
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64

Links:

Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh… http://ow.ly/sijt50Lz2GJ
Dr. Rachel Tate
uptoTate
13-11-2022
×